Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DIM1 rRNA methyltransferase and ribosome maturation factor (DIMT1) is an enzyme essential for the biogenesis of the small ribosomal subunit in eukaryotes[1][2][3]. It specifically dimethylates two adjacent adenosines near the decoding site of 18S rRNA, a critical step required for proper pre-rRNA processing and ribosome assembly[1][2][3][5]. This function is conserved from yeast (Dim1) to humans (DIMT1/DIMT1L), but in humans, the modification occurs in the nucleus[1][2][3]. The presence of DIMT1 on ribosomal precursors, rather than its catalytic activity per se, is essential for downstream steps in ribosome maturation, positioning it as a key quality control factor in the maturation process[2][3]. Diseases associated with DIMT1 include Diamond-Blackfan anemia and localized osteosarcoma[1], and its dysregulation may play a role in cancer and other ribosome-related disorders[1]. No small-molecule drugs or clinical inhibitors specifically targeting DIMT1 are currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DIM1 rRNA methyltransferase and ribosome maturation factor (DIMT1).